WallStreetZenWallStreetZen

NASDAQ: ADAP
Adaptimmune Therapeutics PLC Stock Ownership - Who owns Adaptimmune Therapeutics?

Insider buying vs selling

Have Adaptimmune Therapeutics PLC insiders been buying or selling?
Buy
Sell
NameRoleDateSharesPriceValue
Cintia PiccinaChief Commercial Officer2023-01-3111,890$1.87
$22.23kSell
Elliot NorryChief Medical Officer2023-01-172,159$1.86
$4.01kSell
John LungerChief Patient Supply Officer2023-01-174,440$1.86
$8.25kSell
William C. Bertrand Jr.Chief Operating Officer2023-01-174,440$1.86
$8.25kSell
Adrian RawcliffeChief Executive Officer2023-01-1710,057$1.86
$18.69kSell
Elliot NorryChief Medical Officer2023-01-127,449$1.71
$12.71kSell
Adrian RawcliffeChief Executive Officer2023-01-1218,763$1.71
$32.01kSell
John LungerChief Patient Supply Officer2023-01-124,973$1.71
$8.48kSell
William C. Bertrand Jr.Chief Operating Officer2023-01-124,973$1.71
$8.48kSell
William C. Bertrand Jr.Chief Operating Officer2023-01-113,843$1.75
$6.71kSell

1 of 3

ADAP insiders have sold more... subscribe to Premium to read more.
Net Insider Buy/Sell (L12M) Ownership

Be the first to know when ADAP insiders and whales buy or sell their stock.

ADAP Shareholders

What type of owners hold Adaptimmune Therapeutics PLC stock?
Institutional
Insider
Retail
NameHoldSharesValueType
David M. Mott16.45%161,747,668$268.50MInsider
Peter W. Sonsini16.45%161,747,668$268.50MInsider
Forest Baskett16.45%161,747,668$268.50MInsider
Scott D. Sandell16.45%161,747,668$268.50MInsider
Anthony A. Florence Jr.16.45%161,747,668$268.50MInsider
Ravi Viswanathan15.69%154,247,668$256.05MInsider
Peter J. Barris15.69%154,247,668$256.05MInsider
M. James Barrett14.47%142,247,668$236.13MInsider
Patrick J. Kerins14.47%142,247,668$236.13MInsider
New Enterprise Associates 14 LP8.44%82,978,668$137.74MInsider

1 of 3

ADAP vs Biotech Stocks

TickerInst. %Insider %Net Insider (L12M)Net Insider (L3M)
ADAP6.40%93.60%Net SellingNet Selling
RANI6.43%50.57%Net BuyingNet Buying
GRTS40.13%23.92%
SVRA70.08%3.13%Net BuyingNet Buying
KPTI65.08%34.92%Net SellingNet Selling

Adaptimmune Therapeutics Stock Ownership FAQ

Who owns Adaptimmune Therapeutics?

Adaptimmune Therapeutics (NASDAQ: ADAP) is owned by 11.58% institutional shareholders, 169.30% Adaptimmune Therapeutics insiders, and 0.00% retail investors. David M. Mott is the largest individual Adaptimmune Therapeutics shareholder, owning 161.75M shares representing 16.45% of the company. David M. Mott's Adaptimmune Therapeutics shares are currently valued at $268.50M.

If you're new to stock investing, here's how to buy Adaptimmune Therapeutics stock.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.